OM:XVIVO

Stock Analysis Report

Executive Summary

Xvivo Perfusion AB (publ), a medical technology company, provides solutions for organ, tissue, and cell preservation and perfusion in connection with transplantation.

Snowflake

Fundamentals

Flawless balance sheet with high growth potential.


Similar Companies

Share Price & News

How has Xvivo Perfusion's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-4.6%

XVIVO

-0.5%

SE Medical Equipment

1.9%

SE Market


1 Year Return

9.5%

XVIVO

34.2%

SE Medical Equipment

9.6%

SE Market

Return vs Industry: XVIVO underperformed the Swedish Medical Equipment industry which returned 34.2% over the past year.

Return vs Market: XVIVO matched the Swedish Market which returned 9.6% over the past year.


Shareholder returns

XVIVOIndustryMarket
7 Day-4.6%-0.5%1.9%
30 Day-5.6%-0.05%-0.3%
90 Day-6.8%-5.3%0.7%
1 Year9.5%9.5%35.6%34.2%14.3%9.6%
3 Year121.8%121.8%47.0%29.5%31.5%11.9%
5 Year301.0%301.0%70.1%42.0%66.2%30.8%

Price Volatility Vs. Market

How volatile is Xvivo Perfusion's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Xvivo Perfusion undervalued compared to its fair value and its price relative to the market?

598.73x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Undervalued: XVIVO (SEK156.4) is trading above our estimate of fair value (SEK97.88)

Significantly Undervalued: XVIVO is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: XVIVO is poor value based on its PE Ratio (598.7x) compared to the Medical Equipment industry average (44.9x).

PE vs Market: XVIVO is poor value based on its PE Ratio (598.7x) compared to the Swedish market (16.7x).


Price to Earnings Growth Ratio

Low PEG Ratio: XVIVO is poor value based on its PEG Ratio (7.1x)


Price to Book Ratio

PB vs Industry: XVIVO is overvalued based on its PB Ratio (7.3x) compared to the SE Medical Equipment industry average (4.4x).


Next Steps

Future Growth

How is Xvivo Perfusion forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

83.9%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: XVIVO's forecast earnings growth (83.9% per year) is above the savings rate (0.4%).

Earnings vs Market: XVIVO's earnings (83.9% per year) are forecast to grow faster than the Swedish market (8.9% per year).

High Growth Earnings: earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: XVIVO's revenue (28.2% per year) is forecast to grow faster than the Swedish market (4.5% per year).

High Growth Revenue: XVIVO's revenue (28.2% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

High Future ROE: XVIVO's Return on Equity is forecast to be low in 3 years time (14.5%).


Next Steps

Past Performance

How has Xvivo Perfusion performed over the past 5 years?

18.3%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: XVIVO's earnings have grown by 18.3% per year over the past 5 years.

Accelerating Growth: XVIVO's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: XVIVO had negative earnings growth (-46.6%) over the past year, making it difficult to compare to the Medical Equipment industry average (17.3%).


Return on Equity

High ROE: XVIVO's Return on Equity (1.2%) is considered low.


Return on Assets

ROA vs Industry: XVIVO's Return on Assets is below or equal to the Medical Equipment industry average last year.


Return on Capital Employed

ROCE Improving: XVIVO's Return on Capital Employed has declined over the past 3 years.


Next Steps

Financial Health

How is Xvivo Perfusion's financial position?


Financial Position Analysis

Short Term Liabilities: XVIVO's short term assets (SEK297.4M) exceeds its short term liabilities (SEK63.4M)

Long Term Liabilities: XVIVO's short term assets (297.4M) exceeds its long term liabilities (7.5M)


Debt to Equity History and Analysis

Debt Level: XVIVO's debt to equity ratio (1.3%) is considered satisfactory

Reducing Debt: XVIVO's debt to equity ratio has reduced from 9.3% to 1.3% over the past 5 years.

Debt Coverage: XVIVO's debt is well covered by operating cash flow (309.9%).

Interest Coverage: XVIVO's interest payments on its debt are well covered by EBIT (8.1x coverage).


Balance Sheet

Inventory Level: XVIVO has a low level of unsold assets or inventory.

Debt Coverage by Assets: XVIVO's debt is covered by short term assets (assets are 40.949880x debt).


Next Steps

Dividend

What is Xvivo Perfusion's current dividend yield, its reliability and sustainability?

0.21%

Forecast Dividend Yield


Dividend Yield vs Market

companyn/amarketbottom25%1.8%markettop25%4.8%industryaverage1.1%forecastin3Years0.2%

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate XVIVO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate XVIVO's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if XVIVO's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if XVIVO's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of XVIVO's dividend in 3 years as they are not forecast to pay a notable one for the Swedish market.


Next Steps

Management

What is the CEO of Xvivo Perfusion's salary, the management and board of directors tenure and is there insider trading?

3.8yrs

Average management tenure


CEO

Magnus Nilsson (63yo)

8.8yrs

Tenure

0

Dr. Magnus Nilsson, Ph.D., has been the Chief Executive Officer and President of Xvivo Perfusion AB (publ) since 2011 and serves as its Managing Director. Dr. Nilsson served as the Chief Executive Officer  ...


CEO Compensation Analysis

Compensation vs. Market: Magnus's total compensation ($USD0.00) is too low to compare against companies of similar size in the Swedish market ($USD508.49K).

Compensation vs Earnings: Magnus's compensation has been consistent with company performance over the past year.


Management Age and Tenure

3.8yrs

Average Tenure

50yo

Average Age

Experienced Management: XVIVO's management team is considered experienced (3.8 years average tenure).


Board Age and Tenure

1.5yrs

Average Tenure

59.5yo

Average Age

Experienced Board: XVIVO's board of directors are not considered experienced ( 1.5 years average tenure), which suggests a new board.


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Sellkr6,781,40408 Mar 19
Magnus Nilsson
EntityIndividual
Role
Chief Executive Officer
Chief Executive Officer & Managing Director
Shares37,567
Max Pricekr185.00

Ownership Breakdown


Management Team

  • Christer de Flon (70yo)

    Consultant

    • Tenure: 3.8yrs
  • Christoffer Rosenblad (44yo)

    CFO & Executive VP

    • Tenure: 7.8yrs
  • Magnus Nilsson (63yo)

    Chief Executive Officer & Managing Director

    • Tenure: 8.8yrs
  • Pär-Ola Larsson (50yo)

    Marketing and Sales Director of EMEA & Pacific

    • Tenure: 3.8yrs
  • Henrik Isaksson (48yo)

    Director of Operations

    • Tenure: 1yrs

Board Members

  • Gösta Johannesson (60yo)

    Chairman of the Board

    • Tenure: 1.5yrs
    • Compensation: kr205.00k
  • Dag Andresson (58yo)

    Director

    • Tenure: 0.5yrs
  • Camilla Öberg (55yo)

    Director

    • Tenure: 3.4yrs
    • Compensation: kr130.00k
  • Folke Nilsson (69yo)

    Director

    • Tenure: 0yrs
    • Compensation: kr130.00k
  • Yvonne Mårtensson (66yo)

    Director

    • Tenure: 1.5yrs
    • Compensation: kr130.00k
  • Alan Raffensperger (59yo)

    Director

    • Tenure: 1.5yrs
    • Compensation: kr130.00k

Company Information

Xvivo Perfusion AB (publ)'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Xvivo Perfusion AB (publ)
  • Ticker: XVIVO
  • Exchange: OM
  • Founded: 1998
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: kr4.160b
  • Shares outstanding: 26.60m
  • Website: https://www.xvivoperfusion.com

Number of Employees


Location

  • Xvivo Perfusion AB (publ)
  • Box 53015
  • Gothenburg
  • Västra Götaland County
  • 400 14
  • Sweden

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
XVIVOOM (OMX Nordic Exchange Stockholm)YesShare CapitalSESEKOct 2012
XVIP.FOTCPK (Pink Sheets LLC)YesShare CapitalUSUSDOct 2012
0RKLLSE (London Stock Exchange)YesShare CapitalGBSEKOct 2012
XVIVOSBATS-CHIXE (BATS 'Chi-X Europe')YesShare CapitalGBSEKOct 2012

Biography

Xvivo Perfusion AB (publ), a medical technology company, provides solutions for organ, tissue, and cell preservation and perfusion in connection with transplantation. The company offers XVIVO Perfusion Sys ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/14 21:15
End of Day Share Price2019/10/14 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.